Androgen-deprivation therapy (ADT) entails lowering serum testosterone levels to castrate levels and forms a cornerstone of the management of hormone-sensitive advanced prostate cancer; however, the benefit of ADT is partially offset by its detrimental metabolic and cardiovascular adverse effects. ADT decreases insulin sensitivity while promoting dyslipidemia and sarcopenic obesity, which leads to an increased risk of cardiovascular morbidity and potentially mortality. The risk seems to be highest in elderly patients who have had recent cardiovascular events before starting ADT. It is prudent to engage in an individualized risk-benefit discussion and develop a cohesive multidisciplinary management plan to medically optimize and closely observe these patients before and during treatment with ADT.
INTRODUCTION
Prostate cancer is the most commonly diagnosed cancer in men in the United States, estimated to account for almost one in every five new cancer cases. Most patients are diagnosed with locoregional disease, which carries a 5-year relative survival rate of more than 99%. 1 The prognosis of advanced prostate cancer, including metastatic, locally advanced, local high-risk, recurrent high-risk, and progressive disease, is not as favorable, [2] [3] [4] [5] [6] [7] and androgen-deprivation therapy (ADT) remains the mainstay of treatment for these diseases. Although there are conflicting data on overall survival benefit, ADT is also used for the treatment of pathologic node-positive disease at the time of radical prostatectomy and for intermediate-risk disease as shortterm neoadjuvant, concurrent, or adjuvant treatment to radiation. 5, 8 The goal of ADT is to induce hypogonadism. Historically, oral estrogens have been used as the first medical ADT modality. Studies carried out in the 1960s and 1970s on the most widely used agent, diethylstilbestrol, demonstrated comparable efficacy with orchiectomy but with an excess risk of thromboembolic events and cardiovascular mortality. 9 Cyproterone acetate, a progestational antiandrogen, has also fallen out of favor for the treatment of prostate cancer as a result of an unfavorable adverse effect profile, including significant cardiovascular complications, albeit less severe than that of oral estrogens. 10 Today, first-line options for ADT include bilateral orchiectomy, gonadotropin-releasing hormone (GnRH) agonists, or GnRH antagonists, of which GnRH agonists are most commonly used. 4, 11 GnRH agonists stimulate pituitary receptors, which causes an initial temporary increase in luteinizing hormone and folliclestimulating hormone, with an increase in testicular testosterone production before receptor downregulation and a decrease in testosterone levels. GnRH antagonists immediately bind to pituitary receptors, which causes a rapid decrease in luteinizing hormone, follicle-stimulating hormone, and testosterone. Antiandrogens are categorized as androgen receptor blockers, androgen biosynthesis inhibitors, or androgen receptor signaling inhibitors.
To prevent the initial testosterone surge, GnRH agonists are usually administered with androgen receptor blockers. Abiraterone, an androgen biosynthesis inhibitor, irreversibly inhibits CYP450c17, a critical enzyme in androgen production. Enzalutamide, the first approved androgen receptor signaling inhibitor, acts on three key steps to interrupt the androgen signaling pathway. Both abiraterone and enzalutamide have been approved for use in metastatic castration-resistant prostate cancer, and recently, in metastatic hormone-sensitive-or hormone-naïve-disease.
12
Cardiovascular disease represents the most common comorbidity and cause of death among patients with prostate cancer.
11, 13, 14 The risk of cardiovascular disease was found to be higher in patients with prostate cancer compared with the general population. 15 In addition, adverse metabolic and cardiovascular effects of ADT have been a growing concern, as will be discussed here (Fig 1) . A study has demonstrated that patients who received ADT contrary to guideline recommendations had higher odds of developing cardiovascular complications, with no evidence-based benefit for prostate cancer treatment. 7 As such, the initiation of ADT must be balanced against expected therapeutic benefits.
ADT AND BODY COMPOSITION
ADT is linked to a diminution in lean body mass with a gain in fat mass, known as sarcopenic obesity. Studies show a disproportionate decrease in lean body mass up to 5% and an increase in fat mass of approximately 10%. 2, 13, [16] [17] [18] More than 90% of fat accumulation during ADT is subcutaneous rather than intra-abdominal. 3, 16 These changes occurred in approximately 70% of patients, evident in the initial months of treatment with greater changes noted in older patients. ADT AND METABOLIC SYNDROME Along with the metabolic derangements observed with ADT, an increased incidence of metabolic syndrome has been shown in up to 36% to 75% of patients. 3, 11 However, several fundamental differences from the classically defined metabolic ADT AND CARDIOVASCULAR DISEASE The above-mentioned changes create an atherogenic risk profile through which ADT has been proposed to cause cardiovascular disease. A number of studies have demonstrated that ADT is associated with fatal and nonfatal cardiovascular disease events that encompass ischemic heart disease, myocardial infarction, sudden cardiac death or ventricular arrhythmias, cerebrovascular accidents, peripheral artery disease, and venous thromboembolism. 2, 4, 15 Increased risk seems to occur regardless of whether the patient is administered short-or long-term ADT. 3, 6 Implicated mechanisms that underlie the metabolic and atherothrombotic changes of ADT include the loss of androgenmediated inhibition of stem-cell differentiation into adipocytes and free fatty acid mobilization into triglycerides, a decrease in lipolysis, and compromised reverse cholesterol transport from the arteries to the liver. 20 Elevated levels of cytokines, adiponectin, and fibrinogen create an inflammatory milieu that may contribute to both insulin resistance and atherogenesis. 3, 4 Cells that express GnRH receptors are susceptible to GnRH agonist-mediated effects, such as T-cell activation with a subsequent disruption of androgen-mediated modulation of inflammatory responses. These changes could lead to atherosclerotic plaque formation, destabilization, and rupture. 3, 4, 15, 20 Moreover, ADT-associated QT prolongation has also been reported, 6 and alterations in GnRH-induced cardiomyocyte contractility have been noted in animal studies. 21 
CURRENT LITERATURE AND CONTROVERSIES IN ADT AND CARDIOVASCULAR RISK
Patients with prostate cancer with a larger burden of comorbidities are usually older and have a higher risk of noncancer mortality. 22 reported no significant difference in cardiovascular mortality between the two groups. This discrepancy between observational studies and RCTs is best explained by limitations of study design. RCT data suffer from selection bias with exclusion of patients with high cardiovascular risk and from the use of underpowered post hoc analyses to ascertain cardiovascular outcomes that were not initially adjudicated. 26, 27 In contrast, although observational studies require fewer resources and time and could more likely reflect real-world populations, several limitations include the appropriate selection of comparable patients, differences in adherence to treatment, and an inability to identify specific complications in all patients that can lead to outcome-reporting bias.
In light of the growing body of evidence, a joint scientific advisory from the American Heart Association, American Cancer Society, American Urological Association, and American Society for Radiation Oncology was released in 2010 with the goal of raising awareness about the possible link between ADT and cardiovascular risk. 2 This was followed by a safety warning from the US Food and Drug Administration that required GnRH agonist manufacturers to alert users to the risk of diabetes mellitus, cardiovascular disease, sudden cardiac death, and cerebrovascular accidents on product labeling. 28 The cardiovascular risk associated with androgen deprivation not only differs between the various ADT modalities but also by patient-specific factors. In addition, an RCT that compared use of continuous ADT with intermittent ADT in 1,535 patients with metastatic prostate cancer demonstrated similar rates of high-grade cardiovascular adverse events. 37 This finding is consistent with the study by O'Farrell et al, which suggests that the timing of initial ADT use, and not the duration of exposure, is the main factor for increased cardiovascular risk with ADT. The metabolic and cardiovascular effects of the different types of ADT discussed here have been summarized in Table 1 .
MANAGEMENT OF PATIENTS BEFORE AND DURING ADT
Comprehensive assessment of cardiovascular risk factors for primary and secondary prevention of cardiovascular events can mitigate potential morbidity and mortality from the use of ADT. 2, 13 Lifestyle modification counseling should be recommended to all patients receiving ADT to minimize systemic metabolic adverse effects. Tobacco smoking causes systemic inflammation that leads to atherosclerosis and increased thrombotic risk, which combined with decreased testosterone levels as a result of treatment with ADT, greatly enhances a prothrombotic state and accelerates atherosclerosis. Current smokers have an increased risk of death and recurrence of prostate cancer. 13, 42, 43 Tobacco cessation and continued abstinence should be emphasized. In addition, an exercise regimen can counteract changes in body composition-increased fat mass and reduced lean body mass-from ADT. A recent meta-analysis demonstrated that high body mass index before prostate cancer diagnosis portended an increased risk of death, with every 5-kg/m 2 increase in body mass index associated with a 15% higher mortality. 44 Numerous trials on exercise in 46 A diet low in saturated fat and refined carbohydrates can thwart the metabolic effects of ADT on dyslipidemia, insulin resistance, and diabetes mellitus.
Statin therapy as primary prevention should follow the 2013 American College of Cardiology/American Heart Association guideline which recommends a moderate-intensity statin for a 10-year atherosclerotic cardiovascular disease risk of . 7.5%, and a high-intensity statin for patients with diabetes mellitus, LDL . 190 mg/dL, or as secondary prevention in those with a prior history of cardiovascular disease. 51 Statin use has also been associated with reduced risk of advanced and high-grade prostate cancer in one recent meta-analysis; however, the benefit was not observed for patients with low-risk or localized prostate cancer. 52 Use of aspirin demonstrated a similar outcome for patients with high-risk prostate cancer-Gleason score $ 8 and/or T3 or greater disease-as in the statin study, which showed a lower prostate cancer-specific mortality in patients with high-risk nonmetastatic prostate cancer. 53 A study of 92 patients who were treated with a GnRH agonist plus antiandrogen who received daily aspirin 100 mg for primary prevention showed improved survival rates without cardiovascular complications in the aspirin group 54 (95% v 73%; P 5 .003). To demonstrate whether aspirin should be used for primary prevention in all patients with prostate cancer who are treated with ADT requires larger RCTs, but aspirin should be continued for secondary prevention in all patients with preexisting cardiovascular disease. Although ADT has not been associated with increased blood pressure, given the preponderance of other adverse metabolic effects as a result of treatment with ADT and associated cardiovascular risks, it is crucial that screening and management for essential hypertension be carried out, with a target of , 130/80 mmHg, per the most recently updated 2017 American College of Cardiology/ American Heart Association blood pressure guidelines. In addition, antihypertensive medication should be initiated if the 10-year atherosclerotic cardiovascular disease risk is . 10% or there exists a preexisting history of cardiovascular disease. 55 Angiotensin-converting enzyme inhibitors are favored agents as there are data to suggest that they may improve cancer outcomes. 13 Meticulous screening and management of diabetes mellitus in patients receiving ADT can substantially reduce cardiovascular events, as diabetes mellitus is the prime risk factor for cardiovascular disease. Metformin should be considered as the first-line oral hypoglycemic agent for patients receiving ADT. Recent literature and clinical trials have generated great interest with the use of metformin for patients with prostate cancer receiving ADT, given its potential beneficial effect of inhibiting cancer cell proliferation and improving metabolic syndrome that results from treatment with ADT. 13 Key points in the management of patients receiving ADT are summarized in Table 2 .
CONCLUSION
Prostate cancer is a common hormone-sensitive malignancy and androgen deprivation is an essential component of therapy for advanced disease. ADT increases cardiovascular risk by lowering insulin sensitivity and causing dyslipidemia and sarcopenic obesity, thus mimicking metabolic syndrome. Large observational trials have demonstrated that ADT increases cardiovascular risk; however, data on cardiovascular mortality are equivocal. Cardiovascular risk should be discussed and balanced against the benefits for cancer outcomes, and all efforts should be made to optimize the patient before and during therapy to mitigate deleterious effects. A collaborative multidisciplinary approach key to successfully managing the oncologic and cardiac comorbidities of this unique cohort of patients.
